|
Published by: Business Insights
Published: Jan. 1, 2002 - 238 Pages
Table of Contents
Accenture foreword: Genomics-driven forces of change
The mapping of the human genome: Where next?
The opportunity
Finding the right target
Genomics
Proteomics
Structural biology
Finding the right compound
Predictive ADMET
Information enabled chemistry
Simulation and predictive modelling (in silico)
Selecting the right patients
Pharmacogenomics
Advances in drug discovery approaches
Challenges
Foundation technologies
Knowledge management and collaboration
Knowledge management
Collaborative environment
Standards development
Infrastructure and support systems
Data visualization
Affordable super computing
Infrastructure
About the Accenture author
Pradip K. Banerjee, PhD, MBA
About Accenture
Executive Summary
Investigating the genome
Novel research tools
Model organisms
Clinical trials
Predictive toxicology
Pharmaceutical manufacturing
Microbial resistance
Balancing prevention and treatment
Lab chips
Conclusion
Chapter 1 Introduction
Objectives and goals of study
Study scope and format
Methodology
Information sources
Chapter 2 Overview of genomics
What is a gene?
Genes and disease
Genetic variability
Sequence variability
Expression variability
Opportunities arising from genetic variability
The Human Genome Project (HGP)
Gene databases
Chapter 3 Genomics technology & industry
Biochips
Selected competitors in the biochip market
Bioinformatics
Disease targets
Drug target
Gene sequencing
Gene sequence variation detection
Comparative genomics
Genome database arrays
High-throughput genomics
Key high-throughput and systematic approaches for genomic analysis
Lab on achip
Features of lab on a chip systems
Miniaturisation
Integration
Key benefits of lab on a chip systems
High speed
Reduced reagent and labour cost
Improved enterprise-wide productivity
Pharmacogenomics
Pharmacogenomics segment players
Probe array
Proteomics
Sequencing
Single nucleotide polymorphism (SNP)
Genetic variation
SNP genotyping
Competitors in the SNP genotyping segment
Structural genomics
Photolithography
Affymetrix’s GeneChip technology
Instrumentation
Chapter 4 How is genomics revolutionizing healthcare?
Drug discovery and development
Diagnostics
Tissue microarrays for high-throughput molecular profiling of tumour specimens
Genome screening by comparative genomic hybridisation
Toxicogenomics
Gene Logic and Wyeth-Ayerst Research Division
The market for DNA microarrays
DNA chip technology competition
Alternatives to DNA chip technology
Expression profiling
Gene sequencing
Advantages of chip array technology
Higher-throughput identification of rarely-expressed genes
Ability to obtain more gene targets for monogenic and polygenic diseases
Greater flexibility
High degree of accuracy
Applied markets for genomics
Pharma industry-genomics interactions
Genomics and big pharma
The genomics impact
New drug targets
Portfolio strategies
Genomics integration strategies
Investment in genomics
External versus internal genomics capabilities
The diagnostics sector
The services sector
The SNP consortium
Objectives
Membership
Genomics and biopharmaceutical company alliances
A new kind of biotechnology firm
In-house expertise
The US as the focus of genomics investment
Goals
Application of genomics to cancer markets
Chapter 5 Patents
Introduction
Gene patenting
Doubts over the patentability of genes
The nonobvious requirement
Annotation and anticipation
The SNP Consortium
ESTs
Potential conflicts
Chapter 6 Business analysis
Gene expression analysis and proteomics
The drivers of the genomics segment
The Human Genome Project
The role of DNA in human disease
The ageing population
New analytical devices
Mergers and acquisitions
New capital
Productivity
Strategic alliances
Drug approvals
Vertical integration
Gene-based patents
Tools and service companies
Competition
Market opportunities for functional genomics
Human health
Discovery of novel anti-fungal targets for drug discovery
Nutrition
Crop production
Herbicides
Fungicides
Fertilisers
Seeds
Crop outputs
Industrial products
Competition in the genomics sector
The transformation of genomics companies to drug companies
Big pharma
First-generation biotech
Second-generation genomics companies
Strategic alliances
Appendix I: Genomics company profiles
Leading genomic companies
Aclara Biosciences
Business strategy
Affymetrix
Business strategy
Gene expression monitoring
Collaborative partners
Technology licensees
AlphaGene
Amersham Pharmacia Biotech
Applied Biosystems
Aurora Biosciences
AXYS Pharmaceuticals
Clinical Micro Sensors
Motorola Life Sciences
CuraGen Corporation
Business strategy
Collaborative partners
Display Systems Biotech
Gene Logic
Collaborative partners
Genometrix
Collaborative partners
Products
Hyseq
Product applications
Illumina
Alliances
Life science alliances
Chemical detection
Incyte Pharmaceuticals
Corporate strategy
Products
GeneMachines
Business overview
Corporate strategy
Leading products
Luminex
Instruments
Consumables
Nanogen
Paradigm Genetics
Business overview
Corporate strategy
Leading products
Orchid Biosciences
Protogene Laboratories
Rosetta Inpharmatics
Overview
Products
SEQUENOM
HiberGen
Research Genetics
Caliper Technologies
Business overview
Corporate strategy
Leading products
Genentech
Business overview
Corporate strategy
Leading products
Genome Therapeutics
Business overview
Corporate strategy
Genomic Solutions
Business overview
Corporate strategy
Leading products
Genset
Business overview
Corporate strategy
Leading products
Human Genome Sciences
Business overview
Corporate strategy
Leading products
Lynx Therapeutics
Business overview
Corporate strategy
Leading products
Millennium Pharmaceuticals
Business overview
Corporate strategy
Leading products
Myriad Genetics
Business overview
Corporate strategy
Leading product candidates
Nanogen
Business overview
Corporate strategy
Leading product candidates
deCODE Genetics
Discovery services
Database services
Healthcare informatics
Spotfire
Appendix II: Genomics company capsules
ALCARA BioSciences
AlgoNomics
AMITA Databases
AnVil Informatics
Applied Biosystems
Array Genetics
Gene Biotechnologies
BioCarta
Biodatabases
BioRAM Informatics
BioTools Incorporated
Caesar Software
Cambridge Antibody Technology
CELLECTIS
Compugen
CuraGen
Data4s Bioinformatics
DECODON
Discovery Partners International
eBioinformatics
Edinburgh Biocomputing Systems
ePitope Informatics
Genaissance Pharmaceuticals
GeneData
Genetics Computer Group
GenOdyssee SA
Genomica Corporation
GlaxoSmithKline Experimental Research
Glycominds
Hitachi Genetic Systems - MiraiBio
Incellico
Industry Support Programme
InfoPro Solutions
Informagen
Informatics
InforMax
InnaPhase Corporation Website
Inpharmatica
LabBook
LabDB.com
LabVantage Solutions
LION Bioscience
LucID Professional
MathSoft
Matrix Science
MDL Information Systems
Meso Technologies
MiraiBio
Neobase
Ocimum Biosolutions
Oxford GlycoSciences
Oxford Molecular
Pangea Systems
Paracel
PharMatrix
Premier Biosoft International
Prokaria
Proteomes
3rd Millennium
Silicon Genetics
SomaLogic
StrataGem Corporation
Structural Bioinformatics
Synomics
Teogas Systems
Tripos
Viaken Systems
Xanthon
Xenometrix
Appendix III: Glossary of terms
List of Figures
Figure 1.1: The impact of genomics on the pharmaceutical and biotechnology industry
Figure 1.2: The impact of genomics on the pharmaceutical and biotechnology industry
Figure 1.3: Shortened time for drug discovery
Figure 2.4: The DNA double helix
Figure 2.5: The DNA nucleotides
Figure 3.6: Global market for microarrays (DNA chips), 2000-05
Figure 3.7: Global market for bioinformatics, 2000-2005
Figure 3.8: Global market for pharmacogenomics, 2000-05
Figure 4.9: Global market for pharmacogenomics, 2000-05
Figure 6.10: Breakdown of competition in the genomics sector
Figure 6.11: Companies competing in the genomics sector
List of Tables
Table 3.1: Selected companies competing in the SNPs and genes sectors
Table 3.2: Global market for microarrays (DNA chips), 2000-05
Table 3.3: Global market for bioinformatics, 2000-05
Table 3.4: Functional genomics companies building advanced integrated platforms and substantial databases
Table 3.5: Companies using new genomic tools
Table 3.6: Detection technology companies for genomics
Table 3.7: Spotting technology suppliers
Table 3.8: On-chip (in-situ) synthesis market segment
Table 3.9: Non-DNA-based chip suppliers
Table 3.10: Robotics or "lab on a chip" market sector
Table 3.11: Pharmacogenomics segment players
Table 3.12: Global market for pharmacogenomics, 2000-05
Table 3.13: Selected competitors in the SNP genotyping segment
Table 3.14: Scanning and detection technology suppliers
Table 4.15: Genomics pharmaceutical market sector
Table 4.16: Genomics biotechnology market sector
Table 4.17: Genomics diagnostic market sector
Table 4.18: Global market for genomics-based diagnostics, 2000-05
Table 4.19: Applied markets for genomics
Table 4.20: Selected detection technology companies for genomics
Table 4.21: The leading biopharmaceutical companies worldwide, 2000
Table 4.22: Opportunities for molecular-targeting therapeutics for cancer
Table 4.23: The clinical research organizations (CRO) sector
Table 4.24: The emerging company sector
Table 6.25: The leading US biotechnology companies in the genomic sector
Table 6.26: Big pharma: key financial data, 2000
Table 6.27: First-generation biotech: key financial data, 2000
Table 6.28: Second-generation genomics companies: key financial data, 2000
Table 6.29: Selected strategic alliances involving genomic companies
Table 6.30: Summary of selected Affymetrix expression profiling customers
Table 6.31: Summary of Affymetrix selected collaborators and licensees
Table 6.32: CuraGen's suite of integrated technologies
Table 6.33: Hyseq’s product applications
AbstractGenomics is quietly transforming the pharmaceutical industry. Companies are moving from medicinal chemistry based drug discovery and development, to using information provided by genomics. Virtually all of the major pharmaceutical houses have either formed partnerships with genomics firms that began to emerge in the early 1990s or have created in-house genomics divisions. The Genomics Outlook to 2005: Transforming pharmaceutical and diagnostic markets, a report by Business Insights, examines new genomic approaches to drug discovery and development, focusing on how these technologies can be used most effectively and in a high-throughput capacity. Case studies analyzing applications of genomic technologies to specific disease-related research are provided, and future trends and developments are forecast.
Get Full Details About This Report >>
|
